Application of Pharmacogenomics in Drug Discovery and Development:Correlations Between Transcriptional Modulation and Preclinical Safety Observations

Title: Application of Pharmacogenomics in Drug Discovery and Development:Correlations Between Transcriptional Modulation and Preclinical Safety Observations

Volume: 1 Issue: 1

Author(s): Lilian G. Yengi, Qian Xiang, Li Shen, Appavu Chandrasekaran, John Kao and JoAnn Scatina

Affiliation:

Keywords: Non steroidal progestins, preclinical safety assessments, pharmacogenomics, systems biology approach, transcriptional regulation, thyroid hormone regulation

Abstract: An integrated systems biology approach of measuring mRNA, protein and enzyme activity, was used to determine the molecular mechanisms responsible for reductions in thyroid hormone levels observed in rats given 1000 mg/kg/day of a nonsteroidal progesterone agonist (NSP). The effect of NSP on drug metabolizing enzyme (DME) expression was determined in livers from treated and vehicle control rats. In treated males, CYP1A1, CYP2B1, CYP2B2, CYP2C12, CYP3A1 and UGT1A mRNAs increased by 2.2, 31.0, 9.4, 13.0, 6.4 and 2.3 fold, while CYP2C11 and CYP3A2 levels decreased by 4.8 and 15.0 fold respectively. CYP1A, CYP2B and UGT1A enzyme activities increased by 2.9, 6.2 and 1.4 fold while CYP2C and CYP3A activities decreased by 2.2 and 1.8 fold respectively. CYP2B and CYP2C proteins increased by 2.1 and 1.3 fold but CYP2C11, the male-specific isozyme, and CYP3A protein decreased by 2.0 and 1.4 fold respectively. In treated females, CYP1A, CYP2B, CYP2C, CYP3A and UGT activities increased by 1.9, 12.0, 23.0, 13.0 and 2.2 fold respectively; with corresponding increases in mRNA ranging from 1.5 to 783 fold. CYP2B, CYP2C and CYP3A proteins increased by 3.6, 2.2 and 6.4 fold respectively, but CYP2C11 remained unchanged. These data suggest that NSP modulates the transcriptional regulation DME in rats and could account for the observed reductions in thyroid hormones, since UGT conjugation is the main pathway of thyroid hormone elimination in rats. These data also show gender and isozyme-specific regulation of some genes, thus demonstrating the value of an integrated approach in determining the contribution of individual genes in drug safety and metabolism observations.

Cite this article as:

Yengi G. Lilian, Xiang Qian, Shen Li, Chandrasekaran Appavu, Kao John and Scatina JoAnn, Application of Pharmacogenomics in Drug Discovery and Development:Correlations Between Transcriptional Modulation and Preclinical Safety Observations, Drug Metabolism Letters 2007; 1 (1) . https://dx.doi.org/10.2174/187231207779814274